Return to Today's science sparks archives

Information Click the tweet icon above each article title to share it on Twitter.

2011-12-30

Fig 1. Box-chart representation of mRNA expression of CD133 (A) and CD44 (B) in various soft tissue sarcomas and GIST using the U133A chip.

Fig 1. Box-chart representation of mRNA expression of CD133 (A) and CD44 (B) in various soft tissue sarcomas and GIST using the U133A chip.
  • Chen J, Guo T, Zhang L, Qin LX, Singer S, Maki RG, Taguchi T, Dematteo R, Besmer P, Antonescu CR

  • Genes Chromosomes Cancer. 2012 Feb;51(2):186-95.

2011-12-29

Fig 1f. Fluorescent microscopy demonstrating quiescent PSC (F) loss of lipid droplets (red), [alpha]-SMA Expression (green), and nucleus (blue).

Fig 1f. Fluorescent microscopy demonstrating quiescent PSC (F) loss of lipid droplets (red), [alpha]-SMA Expression (green), and nucleus (blue).
  • Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH

  • Pancreas. 2011 May;40(4):557-66.

2011-12-28

Fig 1. Role of Phenylalanine Residues in Human GLTP-Fold Functionality.

Fig 1. Role of Phenylalanine Residues in Human GLTP-Fold Functionality.
  • Samygina VR, Popov AN, Cabo-Bilbao A, Ochoa-Lizarralde B, Goni-de-Cerio F, Zhai X, Molotkovsky JG, Patel DJ, Brown RE, Malinina L

  • Structure. 2011 Nov 9;19(11):1644-54.

2011-12-27

Fig 2. Outside biopsy. (A) Chronically sun-damaged skin. Rare keratinocytes have enlarged nuclei (arrow) (hematoxylin-eosin, original magnification × 200).

Fig 2. Outside biopsy. (A) Chronically sun-damaged skin. Rare keratinocytes have enlarged nuclei (arrow) (hematoxylin-eosin, original magnification × 200).
  • Lee EH, Busam KJ

  • Dermatol Surg. 2011 Nov;37(11):1689-92

2011-12-23

Fig 2. Scatterplot of number of lesion biopsies by observation years by lesion type.

Fig 2. Scatterplot of number of lesion biopsies by observation years by lesion type.
  • Kovalyshyn I, Dusza SW, Siamas K, Halpern AC, Argenziano G, Marghoob AA

  • Arch Dermatol. 2011 Nov;147(11):1269-75.

2011-12-22

Fig 1. Roadmap: This figure graphically describes the content of this white paper.

Fig 1. Roadmap: This figure graphically describes the content of this white paper.
  • Swartz RJ, Schwartz C, Basch E, Cai L, Fairclough DL, McLeod L, Mendoza TR, Rapkin B; SAMSI Psychometric Program Longitudinal Assessment of Patient-Reported Outcomes Working Group

  • Qual Life Res. 2011 Oct;20(8):1159-67.
Open Access button

2011-12-21

Fig 1. Planar cell polarity and tissue elongation in the Drosophila wing.

Fig 1. Planar cell polarity and tissue elongation in the Drosophila wing.
  • Vichas A, Zallen JA

  • Semin Cell Dev Biol. 2011 Oct;22(8):858-64.

2011-12-20

Fig.4. Kaplan-Meier plot of OS in patients receiving azacitidine (n = 55) or conventional care regimens (CCR; n = 58).

Fig.4. Kaplan-Meier plot of OS in patients receiving azacitidine (n = 55) or conventional care regimens (CCR; n = 58).
  • Rosenblat TL, Jurcic JG

  • Hematol Oncol Clin North Am. 2011 Dec;25(6):1189-213.

2011-12-19

Fig 1. Image of a 48-year-old man before and after treatment of oral melanoma and lesion.

Fig 1. Image of a 48-year-old man before and after treatment of oral melanoma and lesion.
  • Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD

  • J Clin Oncol. 2011 Nov 20;29(33):e809-11.

2011-12-16

Fig 2. Autophagy machinery in host cells controls the fate of starving internalized cells. (a) Left, model depicting the multiple cell fates of internalized cells; the arrow thickness represents the relative frequency of events.

Fig 2. Autophagy machinery in host cells controls the fate of starving internalized cells. (a) Left, model depicting the multiple cell fates of internalized cells; the arrow thickness represents the relative frequency of events.
  • Florey O, Kim SE, Sandoval CP, Haynes CM, Overholtzer M

  • Nat Cell Biol. 2011 Oct 16;13(11):1335-43.

2011-12-15

Fig 2.Integration Procedure and CoxPath Methodology.

Fig 2.Integration Procedure and CoxPath Methodology.
  • Mankoo PK, Shen R, Schultz N, Levine DA, Sander C

  • PLoS One. 2011;6(11):e24709.
Open Access button

2011-12-14

Fig 1. Trafficking of circulating monocyte subsets.

Fig 1. Trafficking of circulating monocyte subsets.
  • Shi C, Pamer EG

  • Nat Rev Immunol. 2011 Oct 10;11(11):762-74.

2011-12-13

Fig 1. This figure demonstrates VZV titers in 14 patients given a second varicella vaccine following lack of response to initial immunization.

Fig 1. This figure demonstrates VZV titers in 14 patients given a second varicella vaccine following lack of response to initial immunization.
  • Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN

  • Biol Blood Marrow Transplant. 2011 Nov;17(11):1708-13.

2011-12-12

Figure I. Digestion curves for four different ∼60 bp segments of yeast chromatin.

Figure I. Digestion curves for four different ∼60 bp segments of yeast chromatin.
  • Wang X, Bai L, Bryant GO, Ptashne M

  • Trends Genet. 2011 Dec;27(12):487-92.

2011-12-09

Fig 7. Invasive mucinous adenocarcinoma. This area of invasive mucinous adenocarcinoma shows a pure lepidic growth.

Fig 7. Invasive mucinous adenocarcinoma. This area of invasive mucinous adenocarcinoma shows a pure lepidic growth.
  • Travis WD

  • Clin Chest Med. 2011 Dec;32(4):669-92.

2011-12-08

Fig 1. Masking of chemokine signals through intratumoral production of RNS.

Fig 1. Masking of chemokine signals through intratumoral production of RNS.
  • Schaer DA, Lesokhin AM, Wolchok JD

  • J Exp Med. 2011 Sep 26;208(10):1937-40.

2011-12-07

Fig 7. Digitally stained confocal mosaic and histology for the excision of normal skin that was shown in Fig 6.

Fig 7. Digitally stained confocal mosaic and histology for the excision of normal skin that was shown in Fig 6.
  • Bini J, Spain J, Nehal K, Hazelwood V, DiMarzio C, Rajadhyaksha M

  • J Biomed Opt. 2011 Jul;16(7):076008.

2011-12-06

Fig 1: Rad50 coiled-coil mutants. (a) Mre11 complexes in the process of bridging sisters.

Fig 1: Rad50 coiled-coil mutants. (a) Mre11 complexes in the process of bridging sisters.
  • Hohl M, Kwon Y, Galván SM, Xue X, Tous C, Aguilera A, Sung P, Petrini JH

  • Nat Struct Mol Biol. 2011 Sep 4;18(10):1124-31.

2011-12-05

Fig 3. Frozen H&E-stained pathology of excised tissue from Mohs surgery.

Fig 3. Frozen H&E-stained pathology of excised tissue from Mohs surgery.
  • Abeytunge S, Li Y, Larson B, Toledo-Crow R, Rajadhyaksha M

  • J Biomed Opt. 2011 May;16(5):050504.
Open Access button

2011-12-02

Fig 2. En1 is expressed in bands of Purkinje cells and in subsets of interneurons, radial glia, granule cell precursors, and DCN neurons at E17.5. A Schematic of cell types and location within a representative coronal section from an E17.5 cerebellum.

Fig 2. En1 is expressed in bands of Purkinje cells and in subsets of interneurons, radial glia, granule cell precursors, and DCN neurons at E17.5. A Schematic of cell types and location within a representative coronal section from an E17.5 cerebellum.
  • Wilson SL, Kalinovsky A, Orvis GD, Joyner AL

  • Cerebellum. 2011 Sep;10(3):356-72.

2011-12-01

Fig 2e. Proposed Hsp90 species in K562 cells, in complex with both aberrant, Bcr-Abl, and normal, c-Abl, proteins. PU-H71, but not H9010, selects for the Hsp90 population that is Bcr-Abl oncoprotein bound.

Fig 2e. Proposed Hsp90 species in K562 cells, in complex with both aberrant, Bcr-Abl, and normal, c-Abl, proteins. PU-H71, but not H9010, selects for the Hsp90 population that is Bcr-Abl oncoprotein bound.
  • Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes Dagama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G

  • Nat Chem Biol. 2011 Sep 25;7(11):818-26.

2011-11-29

Fig 1. Graph shows estimated cumulative incidence curves for detection with MR imaging and detection with mammography as competing events for each type of breast density.

Fig 1. Graph shows estimated cumulative incidence curves for detection with MR imaging and detection with mammography as competing events for each type of breast density.
  • Sung JS, Malak SF, Bajaj P, Alis R, Dershaw DD, Morris EA

  • Radiology. 2011 Nov;261(2):414-20.

2011-11-28

Fig 1. The surgical learning curve for reoperative surgery required after implantation of an artificial urinary sphincter (AUS).

Fig 1. The surgical learning curve for reoperative surgery required after implantation of an artificial urinary sphincter (AUS).
  • Sandhu JS, Maschino AC, Vickers AJ

  • Eur Urol. 2011 Dec;60(6):1285-90.

2011-11-23

Fig 1. MicroRNA sequencing profile in human stem cells.

Fig 1. MicroRNA sequencing profile in human stem cells.
  • Lipchina I, Elkabetz Y, Hafner M, Sheridan R, Mihailovic A, Tuschl T, Sander C, Studer L, Betel D

  • Genes Dev. 2011 Oct 15;25(20):2173-86.
Open Access button

2011-11-22

Fig 1a. T cell activation begins with interaction of the T cell receptor (TCR) on a T cell with major histocompatibility complex (MHC) bound to antigen on an antigen-presenting cell (APC).

Fig 1a. T cell activation begins with interaction of the T cell receptor (TCR) on a T cell with major histocompatibility complex (MHC) bound to antigen on an antigen-presenting cell (APC).
  • Sharma P, Wagner K, Wolchok JD, Allison JP

  • Nat Rev Cancer. 2011 Oct 24;11(11):805-12.

2011-11-21

Fig 1. An example of focal reirradiation (Re-RT) for recurrent medulloblastoma after prior posterior fossa boost radiation (RT1) is shown. The red isodose line represents the prescription dose. Abbreviation: Gy, grays.

Fig 1. An example of focal reirradiation (Re-RT) for recurrent medulloblastoma after prior posterior fossa boost radiation (RT1) is shown. The red isodose line represents the prescription dose. Abbreviation: Gy, grays.
  • Bakst RL, Dunkel IJ, Gilheeney S, Khakoo Y, Becher O, Souweidane MM, Wolden SL

  • Cancer. 2011 Nov 1;117(21):4977-82.

2011-11-18

Fig 1. Prone breast radiation. The breast falls anteriorly toward the ground, with two tangential beams enveloping the whole breast.

Fig 1. Prone breast radiation. The breast falls anteriorly toward the ground, with two tangential beams enveloping the whole breast.
  • Ho A, Morrow M

  • Oncologist. 2011;16(10):1367-79.

2011-11-17

Fig 5a. Global mRNA expression in marker-positive human prostate tumour cells.

Fig 5a. Global mRNA expression in marker-positive human prostate tumour cells.
  • Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI

  • Nat Commun. 2011 Jan;2(1):162.
Open Access button

2011-11-16

Fig 1a. Photomicrographs of a representative case of GTNI stained with H&E.

Fig 1a. Photomicrographs of a representative case of GTNI stained with H&E.
  • Huse JT, Nafa K, Shukla N, Kastenhuber ER, Lavi E, Hedvat CV, Ladanyi M, Rosenblum MK

  • Acta Neuropathol. 2011 Sep;122(3):367-9.
Open Access button

2011-11-15

Fig 2i. 3D-reconstructions of melanomas depict injected cells at 36 h after adoptive transfer.

Fig 2i. 3D-reconstructions of melanomas depict injected cells at 36 h after adoptive transfer.
  • Kircher MF, Gambhir SS, Grimm J

  • Nat Rev Clin Oncol. 2011 Sep 27;8(11):677-88.

2011-11-14

Fig 3. Punch biopsies of left upper chest and left breast were performed.

Fig 3. Punch biopsies of left upper chest and left breast were performed.
  • Balagula Y, Lopez NJ, Busam KJ, Quigley EA

  • Arch Dermatol. 2011 Oct;147(10):1215-20.

2011-11-11

Fig 1. The Spliceosome and Mutations in Multiple Members of Genes Encoding Spliceosomal Proteins.

Fig 1. The Spliceosome and Mutations in Multiple Members of Genes Encoding Spliceosomal Proteins.
  • Abdel-Wahab O, Levine R

  • Cancer Cell. 2011 Oct 18;20(4):420-2.

2011-11-10

Fig 2. PFS by BRCA status.

Fig 2. PFS by BRCA status.
  • Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D

  • Gynecol Oncol. 2011 Nov;123(2):196-9.

2011-11-09

Fig 1. Targeting the type 1 insulin-like growth factor (IGF-1) pathway with octreotide, AMG 479, and metformin.

Fig 1. Targeting the type 1 insulin-like growth factor (IGF-1) pathway with octreotide, AMG 479, and metformin.
  • Dickler MN

  • J Clin Oncol. 2011 Oct 10;29(29):3846-8

2011-11-08

Fig 1. Prognostic immune markers in NSCLC.

Fig 1. Prognostic immune markers in NSCLC.
  • Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS

  • Clin Cancer Res. 2011 Aug 15;17(16):5247-56.

2011-11-07

Fig 3. Heatmap of TTF-1, p63, CK5/6, and 34βE12 coexpression profiles in adenocarcinoma vs squamous cell carcinoma.

Fig 3. Heatmap of TTF-1, p63, CK5/6, and 34βE12 coexpression profiles in adenocarcinoma vs squamous cell carcinoma.
  • Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL

  • Mod Pathol. 2011 Oct;24(10):1348-59.

2011-11-04

Fig 2. High-content screening workflow. Compounds were plated at 10 μmol/L final concentration in 384-well plates before dual cell seeding.

Fig 2. High-content screening workflow. Compounds were plated at 10 μmol/L final concentration in 384-well plates before dual cell seeding.
  • Rao TD, Rosales N, Spriggs DR

  • Mol Cancer Ther. 2011 Oct;10(10):1939-48.

2011-11-03

Fig 4. Cell proliferation within the grafts.

Fig 4. Cell proliferation within the grafts.
  • Major T, Menon J, Auyeung G, Soldner F, Hockemeyer D, Jaenisch R, Tabar V

  • PLoS One. 2011;6(9):e24687.
Open Access button

2011-11-02

Fig 2. Histopathologic review revealed a compound melanocytic nevus with features of a dysplastic nevus containing nests of nevomelanocytes with abundant pale or clear cytoplasm ("balloon cell" changes).

Fig 2. Histopathologic review revealed a compound melanocytic nevus with features of a dysplastic nevus containing nests of nevomelanocytes with abundant pale or clear cytoplasm ("balloon cell" changes).
  • Jaimes N, Braun RP, Stolz W, Busam KJ, Marghoob AA

  • J Am Acad Dermatol. 2011 Oct;65(4):e119-20.

2011-11-01

Fig 3. Patient with solitary plasmacytoma. The use of PET/CT planning resulted in the reduction of treatment volume. The color depiction demonstrates a significant reduction in the dose delivered to normal structures with treatment of the PET/CT-derived volume.

Fig 3. Patient with solitary plasmacytoma. The use of PET/CT planning resulted in the reduction of treatment volume. The color depiction demonstrates a significant reduction in the dose delivered to normal structures with treatment of the PET/CT-derived volume.
  • Terezakis SA, Hunt MA, Kowalski A, McCann P, Schmidtlein CR, Reiner A, Gönen M, Kirov AS, Gonzales AM, Schöder H, Yahalom J

  • Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):615-22.

2011-10-31

Fig 1. Osteosarcoma tissue microarray. Low magnification (×0.3) of human osteosarcoma specimens stained with H&E.

Fig 1. Osteosarcoma tissue microarray. Low magnification (×0.3) of human osteosarcoma specimens stained with H&E.
  • Osborne TS, Ren L, Healey JH, Shapiro LQ, Chou AJ, Gorlick RG, Hewitt SM, Khanna C

  • J Pediatr Hematol Oncol. 2011 Oct;33(7):524-8.

2011-10-28

Fig 1. Trocar arrangement during robot-assisted thoracoscopic phase. la, left robotic arm; a, assistant port; ca, robotic camera arm; ra, right robotic arm (Boone et al.22).

Fig 1. Trocar arrangement during robot-assisted thoracoscopic phase. la, left robotic arm; a, assistant port; ca, robotic camera arm; ra, right robotic arm (Boone et al.22).
  • Twaddell WS, Wu PC, Verhage RJ, Feith M, Ilson DH, Schuhmacher CP, Luketich JD, Brücher B, Vallböhmer D, Hofstetter WL, Krasna MJ, Kandioler D, Schneider PM, Wijnhoven BP, Sontag SJ

  • Ann N Y Acad Sci. 2011 Sep;1232(1):265-291.

2011-10-27

Fig 1b. Region of interest placed on the gallbladder neck (arrow).

Fig 1b. Region of interest placed on the gallbladder neck (arrow).
  • Wang X, Shah RP, Maybody M, Brown KT, Getrajdman GI, Stevenson C, Petre EN, Solomon SB

  • J Vasc Interv Radiol. 2011 Oct;22(10):1414-9.

2011-10-26

Fig 1a. Color Doppler image shows heterogeneous 3.8-cm right renal mass with marked flow.

Fig 1a. Color Doppler image shows heterogeneous 3.8-cm right renal mass with marked flow.
  • Gerst S, Hann LE, Li D, Gonen M, Tickoo S, Sohn MJ, Russo P

  • AJR Am J Roentgenol. 2011 Oct;197(4):897-906.

2011-10-25

Fig 1a. Immunohistochemical staining of three different nodular sclerosis cHL samples using an anti-CT7 antibody (CT7-33). (a) Diffuse positivity.

Fig 1a. Immunohistochemical staining of three different nodular sclerosis cHL samples using an anti-CT7 antibody (CT7-33). (a) Diffuse positivity.
  • Inaoka RJ, Jungbluth AA, Baiocchi OC, Assis MC, Hanson NC, Frosina D, Tassello J, Bortoluzzo AB, Alves AC, Colleoni GW

  • BMC Cancer. 2011 Sep 28;11(1):416.
Open Access button

2011-10-24

Fig 2. Separation of disease-associated and polymorphic variants by functional impact score.

Fig 2. Separation of disease-associated and polymorphic variants by functional impact score.
  • Reva B, Antipin Y, Sander C

  • Nucleic Acids Res. 2011 Sep 1;39(17):e118.
Open Access button

2011-10-21

Fig 4. Diagrammatic representation of the mTOR and hypoxia-induced pathways. Blunt-ended arrows indicate inhibitory effects in the targeted molecule.

Fig 4. Diagrammatic representation of the mTOR and hypoxia-induced pathways. Blunt-ended arrows indicate inhibitory effects in the targeted molecule.
  • Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ

  • Am J Surg Pathol. 2011 Oct;35(10):1549-56.

2011-10-20

Fig 1a. miR-17∼92 suppresses cell death in Eμ-Myc lymphomas. Schematic representation of the miR-17∼92 cluster.

Fig 1a. miR-17∼92 suppresses cell death in Eμ-Myc lymphomas. Schematic representation of the miR-17∼92 cluster.
  • Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A

  • Genes Dev. 2009 Dec 15;23(24):2806-11.

2011-10-19

Fig 1. Education of developing NK cells and thymocytes.

Fig 1. Education of developing NK cells and thymocytes.
  • Sun JC, Lanier LL

  • Nat Rev Immunol. 2011 Aug 26;11(10):645-57.

2011-10-18

Fig 4. Type and number of viral infections. Serious viral infections decreased markedly after day 60 post-CBT.

Fig 4. Type and number of viral infections. Serious viral infections decreased markedly after day 60 post-CBT.
  • Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN

  • Biol Blood Marrow Transplant. 2011 Oct;17(10):1460-71.

2011-10-17

Fig 2a. Prostate-specific antigen drift: A slow rise in PSA after an initial rapid decline with no evidence of radiographic or clinical progression for 28 months while receiving MDV3100.

Fig 2a. Prostate-specific antigen drift: A slow rise in PSA after an initial rapid decline with no evidence of radiographic or clinical progression for 28 months while receiving MDV3100.
  • Scher HI, Morris MJ, Basch E, Heller G

  • J Clin Oncol. 2011 Sep 20;29(27):3695-704.

2011-10-14

Fig 7. Effects of Induction of Soluble RTKs by Intronic PolyA Activation.

Fig 7. Effects of Induction of Soluble RTKs by Intronic PolyA Activation.
  • Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, Henke E, Cartegni L

  • Mol Cell. 2011 Sep 16;43(6):927-39.

2011-10-13

Fig 2. The origins of ovarian cancer.

Fig 2. The origins of ovarian cancer.
  • Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR

  • Nat Rev Cancer. 2011 Sep 23;11(10):719-25.

2011-10-12

Fig 3. Comparison of junctional regions above the ligand-binding pockets in the dG and guanine riboswitches. (a) Alignment of G33 in the structure of the dG riboswitch. (b) Alignment of A24 in the structure of the guanine riboswitch.

Fig 3. Comparison of junctional regions above the ligand-binding pockets in the dG and guanine riboswitches. (a) Alignment of G33 in the structure of the dG riboswitch. (b) Alignment of A24 in the structure of the guanine riboswitch.
  • Pikovskaya O, Polonskaia A, Patel DJ, Serganov A

  • Nat Chem Biol. 2011 Aug 14;7(10):748-55.

2011-10-11

Fig 1. Kaplan-Meier analyses indicating differences in overall and melanoma-specific survival between patients who had surgery and patients who did not have surgery stratified by race.

Fig 1. Kaplan-Meier analyses indicating differences in overall and melanoma-specific survival between patients who had surgery and patients who did not have surgery stratified by race.
  • Collins KK, Fields RC, Baptiste D, Liu Y, Moley J, Jeffe DB

  • Ann Surg Oncol. 2011 Oct;18(10):2925-36.

2011-10-10

Fig 6. Mislocalization of the E4 cells in end-3(−) embryos leads to an improper increase of ref-1 expression in Ear daughters along with a corresponding decrease in Epl daughters.

Fig 6. Mislocalization of the E4 cells in end-3(−) embryos leads to an improper increase of ref-1 expression in Ear daughters along with a corresponding decrease in Epl daughters.
  • Boeck ME, Boyle T, Bao Z, Murray J, Mericle B, Waterston R

  • Dev Biol. 2011 Oct 15;358(2):345-55.

2011-10-07

Fig 1. Sequence and structure of the E. siraeum THF riboswitch.

Fig 1. Sequence and structure of the E. siraeum THF riboswitch.
  • Huang L, Ishibe-Murakami S, Patel DJ, Serganov A

  • Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14801-6.

2011-10-06

Fig 1. RtcB can perform eukaryal tRNA splicing in vivo.

Fig 1. RtcB can perform eukaryal tRNA splicing in vivo.
  • Tanaka N, Meineke B, Shuman S

  • J Biol Chem. 2011 Sep 2;286(35):30253-7.

2011-10-05

Fig 1. MAPK signalling pathway.

Fig 1. MAPK signalling pathway.
  • Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD

  • Lancet Oncol. 2011 Sep;12(9):913-22.

2011-10-04

Fig 3. (A-D) Dose distribution for 3-dimensional radiotherapy (A and C) versus intensity-modulated radiotherapy (B and D) are illustrated.

Fig 3. (A-D) Dose distribution for 3-dimensional radiotherapy (A and C) versus intensity-modulated radiotherapy (B and D) are illustrated.
  • Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT

  • Cancer. 2011 Aug 1;117(15):3342-51.

2011-10-03

Fig. 3. Relative hazard for disease-recurrence according to GGT (median GGT 16.0 U/L) levels with 95% nonparametric CI.

Fig. 3. Relative hazard for disease-recurrence according to GGT (median GGT 16.0 U/L) levels with 95% nonparametric CI.
  • Polterauer S, Hofstetter G, Grimm C, Rahhal J, Mailath-Pokorny M, Kohl M, Concin N, Tempfer C, Marth C, Reinthaller A

  • Gynecol Oncol. 2011 Sep;122(3):590-4.